1. Ette EI, Williams PJ. Pharmacometrics: the science of quantitative pharmacology. Hoboken (NJ): John Wiley, 2007
2. FDA. Guidance for industry: population pharmacokinetics. US Department of Health and Human Services; Food and Drug Administration; Centre for Drug Evaluation and Research & Centre for Biologics Evaluation and Research, 1999 Feb; CP 1 [online]. Available from URL: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072137.pdf?utm_campaign=Google2&utm_source=fdaSearch&utm_medium=website&utm_term=Guidanceforindustrypopulationpharmacokinetics&utm_content=1 [Accessed 2011 Sep 1]
3. EMA. Guideline on reporting the results of population pharmacokinetic analyses. European Medicines Agency 21 June 2007 (Doc. Ref. CHMP/EWP/185990/06) [online]. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003067.pdf [Accessed 2011 Sep 2]
4. Wade JR, Edholm M, Salmonson T. A guide for reporting the results of population pharmacokinetic analyses: a Swedish perspective. AAPS J 2005; 7:45
5. Hennig S, Wainwright CE, Bell SC, et al. Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients. Clin Pharmacokinet 2006; 45: 1099–114